FLFeng Liu

Feng Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Feng Liu has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pre-existing cross-reactive immunity to highly pathogenic avian influenza 2.3.4.4b A(H5N1) virus in the United States

    by Zhu-Nan Li, Feng Liu, Yu-Jin Jung, Stacie Jefferson, Crystal Holiday, F. Liaini Gross, Wen-Pin Tzeng, Paul Carney, Ashley Kates, Ian A. York, et al.

    The unprecedented 2.3.4.4b. A(H5N1) outbreak in dairy cattle, poultry, and spillover to humans in the United States (US) poses a major public health threat. Population immunity is a critical component of influenza pandemic risk assessment. We assessed the pre-existing cross-reactive immunity to 2.3.4.4b A(H5N1) viruses and analyzed 1794 sera from 723 people (0.5–88 yrs) in multiple US geographic regions during 2021–2024. Pre-existing neutralizing and hemagglutinin (HA)-head-binding antibodies to A(H5N1) were low, but there were substantial cross-reactive binding antibodies to N1 neuraminidase (NA) of 2.3.4.4b A(H5N1). Antibodies to group 1 HA stalk were also prevalent and increased with age. A(H1N1)pdm09 infection and influenza vaccination did not induce neutralizing antibodies to A(H5N1) viruses but induced significant rise of functional NA inhibition (NAI) antibodies to N1 of 2.3.4.4b A(H5N1), and group 1 HA stalk antibodies. Moreover, pre-pandemic stockpiled 2.3.4.4c vaccine can elicit cross-reactive neutralizing antibodies to 2.3.4.4b A(H5N1) viruses. Understanding population susceptibility is essential for pandemic preparedness.


  • Top Cited Papers

    Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025

    by Melissa A. Rolfes, Krista Kniss, Marie K. Kirby, Shikha Garg, Katie Reinhart, C. Todd Davis, Erin L. Murray, Debra A. Wadford, Kathleen Harriman, Sophie Zhu, et al.

    Between March 2024 and October 2024, 46 human cases of highly pathogenic avian influenza (HPAI) A(H5N1) had been detected in the United States. The persistent panzootic spread of HPAI A(H5N1) viruses and continued detection of human cases presents an ongoing threat to public health. Between November 2024 and May 2025, an additional 24 cases have been reported for a total of 70 human cases of HPAI A(H5N1): 41 were exposed to dairy cows, 24 to commercial poultry, 2 to backyard poultry, and 3 had an unidentified source of exposure. All sequenced viruses were clade 2.3.4.4b. Overall, 62 cases (89%) reported eye redness, 32 (46%) fever, and 29 (41%) respiratory symptoms; 54 of 67 cases (81%) reported receiving antiviral treatment. Most illnesses were mild; however, four patients were hospitalized. Of the hospitalized patients, three had pneumonia and one died. No human-to-human transmission was detected. Occupational exposure to infected animals was a risk factor for HPAI A(H5N1) virus infection and the risk to the general population remains low; however, the two cases exposed to infected backyard poultry and three cases with unidentified exposures highlight that ongoing vigilance is warranted.


  • Open Access

    Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines

    by Feng Liu, F. Liaini Gross, Sneha Joshi, Manjusha Gaglani, Allison L. Naleway, Kempapura Murthy, Holly C. Groom, Meredith G. Wesley, Laura J. Edwards, Lauren Grant, et al.

    Repeat vaccination with egg-based influenza vaccines could preferentially boost antibodies targeting the egg-adapted epitopes and reduce immunogenicity to circulating viruses. In this randomized trial (Clinicaltrials.gov: NCT03722589), sera pre- and post-vaccination with quadrivalent inactivated egg-based (IIV4), cell culture-based (ccIIV4), and recombinant (RIV4) influenza vaccines were collected from healthcare personnel (18-64 years) in 2018−19 (N = 723) and 2019−20 (N = 684) influenza seasons. We performed an exploratory analysis. Vaccine egg-adapted changes had the most impact on A(H3N2) immunogenicity. In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A(H3N2) virus than ccIIV4 and IIV4. In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses with decreased neutralizing antibody egg/cell ratio. RIV4 also had higher post-vaccination A(H1N1)pdm09 and A(H3N2) HA stalk antibodies in year 1, but there was no significant difference in HA stalk antibody fold rise among vaccine groups in either year 1 or year 2. Multiple seasons of non-egg-based vaccination may be needed to redirect antibody responses from immune memory to egg-adapted epitopes and re-focus the immune responses towards epitopes on the circulating viruses to improve vaccine effectiveness.


  • Open Access

    Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity

    by Min Z. Levine, Crystal Holiday, Yaohui Bai, Weimin Zhong, Feng Liu, Stacie Jefferson, F. Liaini Gross, Wen-Pin Tzeng, Louis Fries, Gale Smith, et al.

    Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibody responses against the 3rd and 5th wave A(H7N9) viruses using the 1st wave vaccine sera from 4 vaccine groups: 1. inactivated vaccine with 2.8 μg hemagglutinin (HA)/dose + AS03A; 2. inactivated vaccine with 5.75 μg HA/dose + AS03A; 3. inactivated vaccine with 11.5 μg HA/dose + MF59; and 4. recombinant virus like particle (VLP) vaccine with 15 μg HA/dose + ISCOMATRIX™. Vaccine group 1 had the highest antibody responses to the vaccine virus and the 3rd/5th wave drifted viruses. Notably, the relative levels of cross-reactivity to the drifted viruses as measured by the antibody GMT ratios to the 5th wave viruses were similar across all 4 vaccine groups. The 1st wave vaccines induced robust responses to the 3rd and Pearl River Delta lineage 5th wave viruses but lower cross-reactivity to the highly pathogenic 5th wave A(H7N9) virus. The population in the United States was largely immunologically naive to the A(H7N9) HA. Seasonal vaccination induced cross-reactive neuraminidase inhibition and binding antibodies to N9, but minimal cross-reactive antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies to A(H7N9).


  • Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination

    by Feng Liu, F. Liaini Gross, Stacie N. Jefferson, Crystal Holiday, Yaohui Bai, Li Wang, Bin Zhou, Min Z. Levine

    A(H3N2) influenza vaccine effectiveness (VE) was low during the 2016–19 seasons and varied by age. We analyzed neutralizing antibody responses to egg- and cell-propagated A(H3N2) vaccine and circulating viruses following vaccination in 375 individuals (aged 7 months to 82 years) across all vaccine-eligible age groups in 3 influenza seasons. Antibody responses to cell- versus egg-propagated vaccine viruses were significantly reduced due to the egg-adapted changes T160K, D225G, and L194P in the vaccine hemagglutinins. Vaccine egg adaptation had a differential impact on antibody responses across the different age groups. Immunologically naive children immunized with egg-adapted vaccines mostly mounted antibodies targeting egg-adapted epitopes, whereas those previously primed with infection produced broader responses even when vaccinated with egg-based vaccines. In the elderly, repeated boosts of vaccine egg-adapted epitopes significantly reduced antibody responses to the WT cell–grown viruses. Analysis with reverse genetic viruses suggested that the response to each egg-adapted substitution varied by age. No differences in antibody responses were observed between male and female vaccinees. Here, the combination of age-specific responses to vaccine egg-adapted substitutions, diverse host immune priming histories, and virus antigenic drift affected antibody responses following vaccination and may have led to the low and variable VE against A(H3N2) viruses across different age groups.


  • Open Access

    Distribution of Peripheral Memory T Follicular Helper Cells in Patients with Schistosomiasis Japonica

    by Xiaojun Chen, Wei Li, Yang Zhang, Xian Song, Lei Xu, Zhipeng Xu, Sha Zhou, Jifeng Zhu, Xin Jin, Feng Liu, et al.

    Schistosomiasis is a helminthic disease that affects more than 200 million people. An effective vaccine would be a major step towards eliminating the disease. Studies suggest that T follicular helper (Tfh) cells provide help to B cells to generate the long-term humoral immunity, which would be a crucial component of successful vaccines. Thus, understanding the biological characteristics of Tfh cells in patients with schistosomiasis, which has never been explored, is essential for vaccine design. In this study, we investigated the biological characteristics of peripheral memory Tfh cells in schistosomiasis patients by flow cytometry. Our data showed that the frequencies of total and activated peripheral memory Tfh cells in patients were significantly increased during Schistosoma japonicum infection. Moreover, Tfh2 cells, which were reported to be a specific subpopulation to facilitate the generation of protective antibodies, were increased more greatly than other subpopulations of total peripheral memory Tfh cells in patients with schistosomiasis japonica. More importantly, our result showed significant correlations of the percentage of Tfh2 cells with both the frequency of plasma cells and the level of IgG antibody. In addition, our results showed that the percentage of T follicular regulatory (Tfr) cells was also increased in patients with schistosomiasis. Our report is the first characterization of peripheral memory Tfh cells in schistosomasis patients, which not only provides potential targets to improve immune response to vaccination, but also is important for the development of vaccination strategies to control schistosomiasis. Schistosomiasis affects more than 200 million people worldwide and causes more than 280,000 deaths per year. Current control strategies are based on chemotherapy, but recurrent reinfection of people living in endemic areas makes researchers search for an effective vaccine to provide long-term protection against schistosomiasis. The generation of long-lived high-affinity antibodies after vaccination is a pivotal step for anti-schistosome vaccine to eliminate schistosomiasis. Considering it is well-known that Tfh cells are specialized effector CD4+ T cells that provide help for germinal center (GC) formation and induce GC B cells to develop protective antibody responses, understanding the biology of Tfh cells in schistosomiasis patients is fundamental for vaccine strategy development. Here, for the first time, we documented increased frequencies of total and activated peripheral memory Tfh cells in schistosomiasis patients. Furthermore, we showed that Tfh2 cells were a major contributor to increased frequency of peripheral memory Tfh cells in patients with schistosomiasis japonica. More importantly, we found the significant correlations of the percentage of Tfh2 cells with both the frequency of plasma cells and the level of total IgG antibody in schistosomiasis patients.


  • Open Access

    AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes

    by Corey P. Mallett, Edith Beaulieu, Marie-Hélène Joly, Benoît Baras, Xiuhua Lu, Feng Liu, Min Z. Levine, Jacqueline M. Katz, Bruce L. Innis, Sandra L. Giannini